Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.

Icli, F.Altundag, K.Coskun, U.Paydas, S.Basaran, G.Saip, P.Dogu, G. G.Eralp, Y.Uslu, R.Sevinc, A.Onur, H.Mandel, N. M.Sezgin, C.Altinbas, M.Guler, N.Isikdogan, A.Gokmen, E.Uygun, K.Ustuner, Z.Yaren, A.2019-10-272019-10-2720110732-183X1527-7755https://doi.org/10.1200/jco.2011.29.15_suppl.629https://hdl.handle.net/11454/44457en10.1200/jco.2011.29.15_suppl.629info:eu-repo/semantics/closedAccessNine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.Conference Object2915WOS:000208880300132Q1